EUVIMEDEUVIMED entdecken
Crossref

Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis

Victoria Murillo iD, Paola Charry, María Suárez-Lledó, Laia Guardia, Cristina Moreno, Joan Cid, Miquel Lozano, Alexandra Pedraza, Raquel Salinas, Vanessa Vilas, Montserrat Duch, Marina Díaz-Beya und 7 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Victoria Murillo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Hauptthemen laut MEDLINE: Cyclophosphamide, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Transplantation, Homologous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the feasibility of using post‐transplant cyclophosphamide (PTCY) prophylaxis in allo‐hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft‐versus‐host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty‐seven adults aged 65 or older with hematological malignancies, undergoing their first allo‐HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2‐year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2‐year overall survival, non‐relapse mortality, cumulative incidence of relapse, and GVHD‐free relapse‐free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY‐based allo‐HCT in older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideHematopoietic Stem Cell TransplantationGraft vs Host DiseaseTransplantation, HomologousHumansAgedMaleFemaleTreatment OutcomeHematologic NeoplasmsTransplantation ConditioningIncidenceAge FactorsImmunosuppressive Agents

Stichwörter der Autor:innen

allogeneic hematopoietic cell transplantationnon‐relapse mortalityolder adultsoutcomespost‐transplant cyclophosphamidetoxicity

Substanzen

CyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Hematology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain.
  • Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Blood Bank Department, Biomedical Diagnostic Center, Banc de Sang i Teixits, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Rehabilitación Clinical Department of Rehabilitation, Hospital Clínic de Barcelona, Barcelona, Spain.

ORCID-Profile: Victoria Murillo

Zitieren

APA

Murillo, V., Charry, P., Suárez-Lledó, M., Guardia, L., Moreno, C., Cid, J., Lozano, M., Pedraza, A., Salinas, R., Vilas, V., Duch, M., Díaz-Beya, M., Rosiñol, L., Esteve, J., Carreras, E., Fernández-Avilés, F., Martínez, C., Rovira, M., & Salas, M. Q. (2024). Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis. European Journal of Haematology. https://doi.org/10.1111/ejh.14291

Vancouver

Murillo V, Charry P, Suárez-Lledó M, Guardia L, Moreno C, Cid J, et al. Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis. European Journal of Haematology. 2024. doi:10.1111/ejh.14291

BibTeX
@article{Murillo2024,
  author = {Murillo, Victoria and Charry, Paola and Suárez-Lledó, María and Guardia, Laia and Moreno, Cristina and Cid, Joan and Lozano, Miquel and Pedraza, Alexandra and Salinas, Raquel and Vilas, Vanessa and Duch, Montserrat and Díaz-Beya, Marina and Rosiñol, Laura and Esteve, Jordi and Carreras, Enric and Fernández-Avilés, Francesc and Martínez, Carmen and Rovira, Montserrat and Salas, María Queralt},
  title = {Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14291}
}
Kostenlos starten →